Recombinant protein bodies as immunogen-specific adjuvants

US9555097B2 · kind B2 · utility

Assignee

• ERA BIOTECH, S.A. · ES

Inventors

• Edward Peter Rybicki · Cape Town, ZA
• Ann Elizabeth Meyers · Silvermist Estate, ZA
• François Devesa · L'Union, FR
• Pablo Marzábal Luna · Barcelona, ES
• Inga Isabel Hitzeroth · Cape Town, ZA
• Peter Öhlschläger · Konstanz, DE

Key dates

• Filing date: Oct 9, 2009
• Grant date: Jan 31, 2017
• Expiry date: Jan 7, 2030

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2740/16322
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

An immunogen-specific is adjuvant for a vaccine or inoculum is disclosed. The adjuvant is comprised of particulate recombinant protein body-like assemblies (RPBLAs) that contain a recombinant fusion protein that contains two portions peptide-linked together. A first portion is a protein body-inducing sequence (PBIS) and a second portion is a T-cell stimulating immunogenic polypeptide whose sequence is that of a pathogenic polypeptide sequence present in or induced by a vaccine or inoculum. The adjuvant, when used as an inoculum in a host animal without a prior priming vaccination or inoculation, does not induce production of antibodies or T cell activation to the pathogenic sequence.